236 related articles for article (PubMed ID: 12189555)
21. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation.
Arvanitakis M; Van Laethem JL; Parma J; De Maertelaer V; Delhaye M; Devière J
Endoscopy; 2004 Jun; 36(6):535-42. PubMed ID: 15202051
[TBL] [Abstract][Full Text] [Related]
23. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma.
Wilentz RE; Chung CH; Sturm PD; Musler A; Sohn TA; Offerhaus GJ; Yeo CJ; Hruban RH; Slebos RJ
Cancer; 1998 Jan; 82(1):96-103. PubMed ID: 9428484
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: cytologic studies and k-ras-2 codon 12 molecular analysis in 47 cases.
Pugliese V; Pujic N; Saccomanno S; Gatteschi B; Pera C; Aste H; Ferrara GB; Nicolò G
Gastrointest Endosc; 2001 Nov; 54(5):595-9. PubMed ID: 11677475
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer.
Urgell E; Puig P; Boadas J; Capellà G; Queraltó JM; Boluda R; Antonijuan A; Farré A; Lluís F; González-Sastre F; Mora J
Eur J Cancer; 2000 Oct; 36(16):2069-75. PubMed ID: 11044643
[TBL] [Abstract][Full Text] [Related]
26. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
27. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
29. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups.
Yan L; McFaul C; Howes N; Leslie J; Lancaster G; Wong T; Threadgold J; Evans J; Gilmore I; Smart H; Lombard M; Neoptolemos J; Greenhalf W
Gastroenterology; 2005 Jun; 128(7):2124-30. PubMed ID: 15940643
[TBL] [Abstract][Full Text] [Related]
30. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis.
Wenger FA; Zieren J; Peter FJ; Jacobi CA; Müller JM
Langenbecks Arch Surg; 1999 Apr; 384(2):181-6. PubMed ID: 10328172
[TBL] [Abstract][Full Text] [Related]
31. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
Su SB; Qin SY; Chen W; Luo W; Jiang HX
World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
[TBL] [Abstract][Full Text] [Related]
32. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
33. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
34. K-ras mutations at codon 12 are rare events in chronic pancreatitis.
Orth M; Gansauge F; Gansauge S; Beger HG; Adler G; Schmid RM
Digestion; 1998; 59(2):120-4. PubMed ID: 9586823
[TBL] [Abstract][Full Text] [Related]
35. Can IL-2R alpha be a valuable marker along with CA 19-9 in the diagnosis of chronic pancreatitis and pancreatic cancer?
Kayhan B; Kayhan B; Akdoğan M
Int J Biol Markers; 2004; 19(3):196-202. PubMed ID: 15503821
[TBL] [Abstract][Full Text] [Related]
36. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
37. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions.
Trümper LH; Bürger B; von Bonin F; Hintze A; von Blohn G; Pfreundschuh M; Daus H
Br J Cancer; 1994 Aug; 70(2):278-84. PubMed ID: 8054276
[TBL] [Abstract][Full Text] [Related]
40. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
